Fundraising Fox

Cardurion Pharmaceuticals, Inc.

Burlington, US · Founded 2017 · Delaware corporation · 5 known investors

Biotech

Founders & leadership

MM
Michael MendelsohnNamed on SEC filing

Board

ER
Evan RachlinBoard director
PL
Peter LawrenceBoard director
EM
Edward MathersBoard director
AKAdam Koppel
Adam KoppelinBoard directorManaging Director at Bain Capital Life Sciences
NDNicholas Downing
Nicholas DowningBoard directorPartner at Bain Capital Life Sciences
JKJeb Keiper
Jeb KeiperinBoard directorInvestor at Third Rock Ventures
DL
Daniel LynchBoard director
ER
Emma ReeveBoard director

Investors · 5

Bain Capital Life SciencesBostonvia Adam M. Koppel · board
Bain Capitalreported
NEA SecondaryreportedTimonium
Polaris PartnersreportedBoston · $500K – $5Mvia Amy Schulman · board
Third Rock VenturesreportedBoston · $100K – $5Mvia Jeb Keiper · board

Reported raises · per SEC filings

Form D private placements

$431.7M disclosed across 5 rounds · 2017–2024

▶$260.4MraisedJul 2024 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Evan RachlinDirector
  • Jeb KeiperDirector
  • Michael MendelsohnExecutive Officer, Director
  • Daniel LynchDirector
  • Emma ReeveDirector
  • Peter LawrenceExecutive Officer, Director
  • Edward MathersDirector
  • Adam KoppelDirector
  • Nicholas DowningDirector
Offering amount
$260.4M
Amount sold
$260.4M
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$128.1MraisedJul 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam KoppelDirector
  • Keith GottesdienerDirector
  • Kenneth NovackDirector
  • Jeb KeiperDirector
  • Nicholas DowningDirector
  • Michael MendelsohnExecutive Officer, Director
  • Peter LawrenceExecutive Officer, Director
Offering amount
$128.1M
Amount sold
$128.1M
Finders' fees
$3.1M
Placement agents
SVB Leerink LLC
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.5MraisedDec 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam KoppelDirector
  • Kenneth NovackDirector
  • Amy SchulmanDirector
  • Peter LawrenceExecutive Officer, Director
  • Nicholas DowningDirector
  • Jeb KeiperDirector
  • Michael MendelsohnExecutive Officer, Director
  • Keith GottesdienerDirector
Offering amount
$17.5M
Amount sold
$17.5M
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedNov 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeb KeiperDirector
  • Amy SchulmanDirector
  • Kenneth NovackDirector
  • Michael MendelsohnExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.7MraisedApr 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MendelsohnExecutive Officer, Director
Offering amount
$22.4M
Amount sold
$15.7M
First sale
Mar 2017
Incorporated
Limited Liability Company, Georgia, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseasesbusinesswire.com · Jul 2024Cardurion Pharmaceuticals Raises $260M in Series B | citybizcitybiz.co · Jul 2024Cardurion Pharmaceuticals Announces Investment of up to $300 Million from Bain Capital - Cardurioncardurion.com · Oct 2021

Frequently asked questions

Who are Cardurion Pharmaceuticals, Inc.'s investors?
Cardurion Pharmaceuticals, Inc.'s investors include Bain Capital Life Sciences, Bain Capital, NEA Secondary, Polaris Partners, Third Rock Ventures.
How much funding has Cardurion Pharmaceuticals, Inc. raised?
Cardurion Pharmaceuticals, Inc. has disclosed $431.7M raised across 5 rounds.
Where is Cardurion Pharmaceuticals, Inc. headquartered?
Cardurion Pharmaceuticals, Inc. is headquartered in Burlington, US.